Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep 2010 Jul;5(3):157-62

Date

05/07/2010

Pubmed ID

20446122

DOI

10.1007/s11899-010-0051-0

Scopus ID

2-s2.0-77955980418   2 Citations

Abstract

Allogeneic hematopoietic cell transplantation is curative for patients with high-risk leukemia, but disease recurrence remains a major cause of treatment failure. New tools are now available to potentially identify patients with minimal residual disease who are at high risk for treatment failure. These improvements in disease detection allow for new opportunities to prevent relapse. The transplant course can be conceptualized into the pretransplant, peritransplant, and posttransplant periods. This article discusses the differing transplant interventions aimed at reducing relapse in each of these periods, focusing on new approaches that are currently being conceived or in early-stage clinical trials.

Author List

Verneris MR, Burke MJ

Author

Michael James Burke MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Cord Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Humans
Leukemia
Leukemia, Myeloid, Acute
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Transplantation, Homologous
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a